Method for assisting diagnosis of hepatocellular cancer
The method of combining CpG methylation analysis of SEPT9 and HOXA1 genes with AFP and PIVKA-II levels in serum enhances the diagnosis of hepatocellular carcinoma, addressing the limitations of current tumor markers and sample volume requirements, thereby improving diagnostic accuracy and efficiency.
Patent Information
- Application Number
- PCT/JP2024/001080
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-01-17
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for diagnosing hepatocellular carcinoma, particularly non-viral cases, face challenges with insufficient sensitivity and specificity due to reliance on tumor markers like AFP and PIVKA-II, which are less accurate and prone to false positives, and require large plasma samples for methylation analysis, making early detection and surveillance inefficient.
A method involving the measurement of CpG methylation levels in the transcriptional regulatory regions of the SEPT9 and HOXA1 genes using a combination of AFP and PIVKA-II levels in serum, employing a two-step restriction enzyme treatment to enhance accuracy and efficiency, allowing for diagnosis with a small serum sample volume.
This approach improves the sensitivity and specificity of hepatocellular carcinoma diagnosis by combining CpG methylation analysis with traditional tumor markers, reducing the need for extensive plasma samples and enhancing early detection capabilities, especially for non-viral cases.
Smart Images

Figure JP2024001080_28112024_PF_FP_ABST
Abstract
Description
Methods for aiding in the diagnosis of hepatocellular carcinoma
[0001] The present invention relates to a method for aiding in the diagnosis of hepatocellular carcinoma in a subject.
[0002] Liver cancer accounts for 830,000 deaths worldwide annually, making it the third leading cause of cancer deaths. Hepatocellular carcinoma (HCC) accounts for 90.1% of primary liver cancers, and the relative 5-year survival rate is 62.9% for Stage I, 45.4% for Stage II, 15.9% for Stage III, and 4.5% for Stage IV according to the TNM Stage classification. The prognosis worsens as the disease progresses, making HCC one of the cancer types with a poor prognosis. Therefore, early detection of HCC is the best way to improve prognosis.
[0003] Examples of tumor markers for hepatocellular carcinoma include alpha-fetoprotein (AFP) and protein induced by vitamin K absorption or antagonist-II (PIVKA-II). AFP, a serum protein specific to the fetal stage produced in the fetal liver and yolk sac, is elevated in hepatocellular carcinoma and is therefore used to diagnose hepatocellular carcinoma. However, AFP is also elevated in cancers other than hepatocellular carcinoma, such as chronic hepatitis, liver cirrhosis, neurodegenerative diseases, and non-seminoma testicular cancer, and therefore its use alone is considered undesirable.
[0004] In addition, in recent years, the number of patients with viral hepatocellular carcinoma has been decreasing, while the number of patients with non-viral hepatocellular carcinoma has been increasing.Under these circumstances, it is known that AFP has a lower AFP value in non-viral hepatocellular carcinoma compared to viral hepatocellular carcinoma, and therefore the detection accuracy of AFP for non-viral hepatocellular carcinoma is poor (see Non-Patent Document 1).Therefore, assuming that the proportion of non-viral hepatocellular carcinoma patients will increase, there is a demand for a technology that can diagnose non-viral hepatocellular carcinoma patients without relying mainly on AFP.
[0005] On the other hand, PIVKA-II is an abnormal prothrombin without coagulation activity that is produced when there is a vitamin K deficiency. When used alone, PIVKA-II has higher sensitivity and specificity than AFP in diagnosing hepatocellular carcinoma. However, PIVKA-II levels increase when warfarin is administered, when cephalosporin antibiotics are used, when there is obstructive jaundice, when there is extremely poor nutritional status, or when there is alcoholic liver damage, resulting in false positives. On the other hand, caution is required when administering vitamin K preparations, as PIVKA-II levels return to normal even when liver cancer is present.
[0006] This simultaneous combined testing of AFP and PIVKA-II is covered by health insurance in Japan for patients with high-risk factors for liver cancer, such as cirrhosis or chronic hepatitis, and the liver cancer treatment guidelines also recommend measuring two or more tumor markers in the diagnosis of small hepatocellular carcinoma.
[0007] Regarding cancer diagnosis based on AFP or PIVKA-II, it has been reported that for early stage hepatocellular carcinoma, AFP alone has a sensitivity of 53% and a specificity of 90%, PIVKA-II alone has a sensitivity of 61% and a specificity of 70%, and the combined use of both improves the sensitivity to 78%, but the specificity is low at 62%, and there are limitations to the use of AFP and PIVKA-II alone in screening for early stage hepatocellular carcinoma (see Non-Patent Document 2).
[0008] In recent years, methods for detecting hepatocellular carcinoma using gene methylation as an indicator have been disclosed. For example, a method for diagnosing hepatocellular carcinoma by performing sodium bisulfite treatment (bisulfite treatment) and detecting the methylation of the SEPT9 gene (see Non-Patent Document 3) has been reported, and it has been reported that the SEPT9 gene is an important epi-driver gene for liver carcinogenesis because the expression of SEPT9 is suppressed by excessive methylation of the CpG sequence of SEPT9, and that the combination of AFP and the methylation degree of the CpG sequence of the SEPT9 gene improves the detection sensitivity and specificity of hepatocellular carcinoma (see Non-Patent Documents 4 and 5).
[0009] On the other hand, the present inventors have focused on the relationship between methylation of CpG sequences and cancer, and have disclosed a method for predicting the presence or absence of colorectal tumors by measuring the methylation level of one or more CpG sequences within or near the transcriptional regulatory region of Twist homolog 1 (Twist 1) (see Patent Document 1), a method for predicting the presence or absence of colorectal tumors by measuring the methylation level of CpG in the TWIST1, NDRG4, BMP3, or SEPT9 gene in stool or serum (see Patent Document 2), a method for diagnosing cancer by measuring the methylation level of CpG in the RUNX3 gene (see Patent Document 3), and the usefulness of a combination of methylated SEPT9 CpG sequences in serum and AFP in diagnosing hepatocellular carcinoma (see Non-Patent Documents 6 and 7).
[0010] Furthermore, it has been disclosed that methylation of the CpG sequence of Homeobox A1 (HOXA1), another tumor marker, may be used in cancer diagnosis when combined with other cancer markers (see Non-Patent Documents 8 to 10).
[0011] Here, in the above Patent Document 1 and Non-Patent Document 2, sodium hydrogen sulfite treatment (bisulfite treatment) is carried out, which has the problem that quantitative determination is lacking when the degree of methylation is low, and therefore a body fluid of 10 mL or more is required for whole blood, and 3.5 mL or more is required for plasma.
[0012] Furthermore, in Patent Document 2, there are six CpG sequences within or near the transcriptional regulatory region of Twist 1, and HhaI, HpaII, and BstUI are used as methylation-sensitive restriction enzymes corresponding to the CpG sequences to cleave each CpG sequence. Here, in methylation-sensitive restriction enzyme treatment, treatment with all restriction enzymes at once results in incomplete cleavage. Therefore, a two-stage restriction enzyme treatment is performed to increase the efficiency of restriction enzyme cleavage and improve the accuracy of methylation detection. However, after one restriction enzyme treatment, it becomes necessary to open the tube lid and add another restriction enzyme to perform restriction enzyme treatment again, which poses problems such as evaporation of approximately 5 to 20% of the restriction enzyme buffer, changing the composition of the restriction enzyme buffer, and the prolonged enzymatic reaction, which makes the DNA more susceptible to denaturation. Furthermore, Patent Document 3 also performs methylation-sensitive restriction enzyme treatment in two stages, as in Patent Document 2. Furthermore, the technology described in Non-Patent Document 9 uses a combination of AFP and AFP-L3 as tumor markers, which are not covered by health insurance in Japan, and analyzes the methylation of three genes, HOXA1, EMX1, and TSPYL5. Therefore, it is considered difficult to put this technology into practical use from the standpoints of insurance eligibility, test efficiency, and test cost.
[0013] International Publication No. 2010 / 113529 Pamphlet International Publication No. 2017 / 043497 Pamphlet Japanese Patent Application Laid-Open No. 2020-14415
[0014] Kawai K. et al., Clinical Characteristics of Non-B, Non-C Liver Cirrhosis Complicated with Hepatocellular Carcinoma: Survey of Non-B, Non-C Liver Cirrhosis in Japan 2011, Kyobunsha 2012; 27-31. Marrero J, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137: 110-118. Abderrahim Oussalah, et al. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. eBioMedicine Volume 30, April 2018, Pages 138-147. Villanueva A, Portela A, Sayols S, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015; 61: 1945-1956.Li B, Huang H, Huang R, et al. SEPT9 Gene methylation as a noninvasive marker for hepatocellular carcinoma. Dis Markers. 2020; 9:6289063.Kotoh Y, Suehiro Y, Saeki I, et al. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun 2020; 4: 461-470.Yamazaki A. et al., Hepatocellular Carcinoma Screening by Liquid Biopsy Using Highly Sensitive DNA Methylation Analysis Technology: Comparison of Diagnostic Performance Between Methylated SST and Methylated SEPT9, Yamaguchi Medical Journal, Vol. 70, No. 3, pp. 89-98, 2021. Paco A, de Bessa Garcia SA, Freitas R. Methylation in HOX Clusters and Its Applications in Cancer Therapy. Cells: 2020; 9: 1613. Chalasani N, Ramasubramanian T, Bhattacharya A, et al. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021; 19: 2597-2605. Kisiel J, Dukek B, Kanipakam R, et al. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. Hepatology. 2019; 69: 1180-1192.
[0015] Various methods have been used to diagnose hepatocellular carcinoma, but their sensitivity and specificity are not sufficient for diagnosis. While a surveillance system for viral hepatocellular carcinoma has been established to some extent, no surveillance system has been established for non-viral hepatocellular carcinoma, the number of patients of which is expected to increase in the future, and early diagnosis through health checkups and other methods is desirable. Therefore, the present invention aims to provide a method for easily detecting hepatocellular carcinoma using body fluids such as serum collected during health checkups and other methods, without relying solely on AFP.
[0016] As a result of intensive research to solve the above-mentioned problems, the inventors have discovered a method for assisting in the diagnosis of hepatocellular carcinoma in a subject by measuring the CpG methylation level in DNA of the transcriptional regulatory region of the SEPT9 gene or the HOXA1 gene in addition to the AFP level or PIVKA-II level in the serum of the subject using a specified method, and evaluating these indicators in combination, thereby completing the present invention.
[0017] That is, the present invention is as follows: [1] A method for assisting in the diagnosis of hepatocellular carcinoma in a subject, comprising measuring (A) the CpG methylation level in the transcriptional regulatory region and / or the region +1 to +1000 of the transcription start site of the SEPT9 gene, or the CpG methylation level in the transcriptional regulatory region and / or the region +1 to +1000 of the transcription start site of the HOXA1 gene in DNA extracted from a body fluid collected from the subject, and (B) the alpha-fetoprotein (AFP) level or the protein induced by vitamin K absorption or antagonist-II (PIVKA-II) level in the body fluid collected from the subject, performing statistical analysis based on at least the two indices (A) and (B), and using the value obtained by the statistical analysis, The methylation level of CpG in the transcriptional regulatory region of the SEPT9 gene and / or the region of the transcription start site +1 to +1000, or the transcriptional regulatory region of the HOXA1 gene and / or the region of the transcription start site +1 to +1000, is measured by: (a) measuring the methylation level of CpG in the transcriptional regulatory region of the SEPT9 gene and / or the region of the transcription start site +1 to +1000 in a reaction vessel by: (ii) adding at least one restriction enzyme selected from HhaI, HpaII, Hpy99I, SacII, SmaI, NotI, AatII, AccI, Aor13HI, Aor51HI, BspT104I, BssHII, Cfr10I, ClaI, CpoI, Eco52I, HaeII, MluI, NaeI, NruI, PmaCI, Psp1406I, PvuI, SalI, and SnaBI, (iii) the restriction enzyme BstUI, and (iv) a restriction enzyme reaction buffer, and sealing the reaction vessel; (b) treating the reaction vessel with the restriction enzyme at a temperature of 30 to 50°C for 0.5 to 16 hours, and then at 50 to 70°C for 0.5 to 20 hours, while keeping the reaction vessel sealed; (c) amplifying a part or all of the region of the transcription regulatory region and / or the region of the transcription start site +1 to +1000 of the gene to be measured using the DNA treated with the restriction enzyme in step (b) as a template; (d) measuring the CpG methylation level in the DNA of the transcription regulatory region and / or the region of the transcription start site +1 to +1000 of the gene to be measured based on the results of the amplification in step (c);
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0070]
[0071]
[0072]
[0073]
[0081]
[0082]
[0083]
[0084]
[0085]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[100]
[101]
[0099]
[0099]
[0099]
[0101]
[0099]
[0099]
[0099]
[0102]
[0099]
[0099]
[0099]
[0099]
[0103]
[0099]
[0099]
[0099]
[0104]
[0099] [00 [4] The method for assisting in the diagnosis of hepatocellular carcinoma according to [1] or [2] above, characterized in that the statistical analysis is performed based on three indices: the CpG methylation level, the AFP level, and the PIVKA-II level in DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the SEPT9 gene; or the CpG methylation level, the AFP level, and the PIVKA-II level in DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the HOXA1 gene. [5] The method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to [1] or [2] above, wherein the hepatocellular carcinoma is non-viral hepatocellular carcinoma. [6] A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to [1] or [2] above, comprising: performing a statistical analysis based on at least the two indicators (A) and (B) above; comparing the value obtained by the statistical analysis with the value obtained by the statistical analysis in a control subject not suffering from hepatocellular carcinoma; and assessing that the subject is highly likely to be suffering from hepatocellular carcinoma when the value obtained by the statistical analysis based on at least the two indicators (A) and (B) above is higher than the value obtained by the statistical analysis in a control subject not suffering from hepatocellular carcinoma.[7] A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to [1] or [2] above, wherein the cytosine of the CpG for which methylation level is measured in the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the SEPT9 gene is the cytosine at position 75,369,591, 75,369,593, 75,369,600, or 75,369,602 of human chromosome 17. [8] A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to [1] or [2] above, wherein the cytosine of the CpG for which methylation level is measured in the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the HOXA1 gene is the cytosine at position 27,095,945 of human chromosome 7. [9] A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to [1] or [2] above, characterized in that the DNA in the transcriptional regulatory region and / or the region +1 to +1000 of the transcription start site that is the target of amplification in step (c) contains a total of one to four sequences recognized by the restriction enzymes used in step (a).
[10] A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to [1] or [2] above, characterized in that, when two or more restriction enzymes are used in step (a), the DNA in the transcriptional regulatory region and / or the region +1 to +1000 of the transcription start site that is the target of amplification in step (c) does not contain a sequence recognized by at least one of the restriction enzymes used in step (a).
[11] A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to [1] or [2] above, characterized in that, in step (a), at least HhaI, HpaII, and BstUI are added to the reaction vessel as restriction enzymes.
[0018] According to the present invention, it is possible to easily assist in the diagnosis of hepatocellular carcinoma in a subject using a small amount of serum or the like.
[0019] 1 is a graph showing the relationship between the number of methylated SEPT9 genes (copy numbers) obtained by a single treatment (condition 1) and the number of copies obtained by a two-stage treatment (condition 2).
[0034] FIG. 1 is a graph showing the relationship between the number of methylated HOXA1 genes (copy numbers) obtained by a single treatment (condition 1) and the number of copies obtained by a two-stage treatment (condition 2).
[0035] FIG. 1 is a graph showing the results of ROC analysis using indicators 1 to 3 out of four indicators, namely, methylated SEPT9 (mSEPT9), methylated HOXA1 (mHOXA1), AFP, and PIVKA-II, in a control group and all viral hepatocellular carcinoma patient groups (Viral All Stage). 1 is a diagram showing the results of ROC analysis when indices 1 to 3 from the four indices mSEPT9, mHOXA1, AFP, and PIVKA-II are used in a non-viral hepatocellular carcinoma patient group (non-Viral All Stage). 2 is a diagram showing the results of ROC analysis when indices 1 to 3 from the four indices mSEPT9, mHOXA1, AFP, and PIVKA-II are used in a early viral hepatocellular carcinoma patient group (Early Viral). 3 is a diagram showing the results of ROC analysis when indices 1 to 3 from the four indices mSEPT9, mHOXA1, AFP, and PIVKA-II are used in a early non-viral hepatocellular carcinoma patient group (Early non-Viral). 1 is a diagram showing the results of determining the AUC values of combinations of AFP, PIVKA-II, and mSEPT9 when they are normally distributed and when they are not normally distributed. 2 is a diagram showing the results of determining the AUC values of combinations of AFP, PIVKA-II, and mHOXA1 when they are normally distributed and when they are not normally distributed. 3 is a diagram showing the results of determining the AUC values and statistical analysis results when AFP, PIVKA-II, and mSEPT9 are all normally distributed in the entire hepatocellular carcinoma. 4 is a diagram showing the results of determining the AUC values, sensitivity, and specificity when AFP, PIVKA-II, and mSEPT9 are all normally distributed in early hepatocellular carcinoma, early non-viral hepatocellular carcinoma, and early viral hepatocellular carcinoma. 5 is a diagram showing the results of determining the AUC values and statistical analysis results when AFP, PIVKA-II, and mHOXA1 are all normally distributed in the entire hepatocellular carcinoma.1 shows the results of determining the AUC value, sensitivity, and specificity when AFP, PIVKA-II, and mHOXA1 are all normally distributed in early stage hepatocellular carcinoma, early stage non-viral hepatocellular carcinoma, and early stage viral hepatocellular carcinoma. 2 shows the relationship between mSEPT9 measurement values and mHOXA1 measurement values when DNA is extracted from 1.0 mL or 0.4 mL of serum specimens.
[0020] The method for assisting in the diagnosis of hepatocellular carcinoma of the present invention comprises measuring (A) the CpG methylation level in the transcriptional regulatory region of the SEPT9 gene and / or the region of the transcription start site +1 to +1000 in the transcriptional regulatory region of the HOXA1 gene, or the region of the transcription start site +1 to +1000 in the transcriptional regulatory region of the HOXA1 gene, in DNA extracted from a body fluid collected from a subject, and (B) the alpha-fetoprotein (AFP) level or protein induced by vitamin K absorption or antagonist-II (PIVKA-II) level in the body fluid collected from the subject, performing a statistical analysis based on at least the two indices (A) and (B), and assisting in the diagnosis of hepatocellular carcinoma in the subject based on the value obtained by the statistical analysis, The methylation level of CpG in the transcriptional regulatory region of the SEPT9 gene and / or the region of the transcription start site +1 to +1000, or the transcriptional regulatory region of the HOXA1 gene and / or the region of the transcription start site +1 to +1000, is measured by: (a) measuring the methylation level of CpG in the transcriptional regulatory region of the SEPT9 gene and / or the region of the transcription start site +1 to +1000 in a reaction vessel by: (ii) adding at least one restriction enzyme selected from HhaI, HpaII, Hpy99I, SacII, SmaI, NotI, AatII, AccI, Aor13HI, Aor51HI, BspT104I, BssHII, Cfr10I, ClaI, CpoI, Eco52I, HaeII, MluI, NaeI, NruI, PmaCI, Psp1406I, PvuI, SalI, and SnaBI, (iii) the restriction enzyme BstUI, and (iv) a restriction enzyme reaction buffer, and sealing the reaction vessel; (b) treating the reaction vessel with the restriction enzyme at a temperature of 30 to 50°C for 0.5 to 16 hours, and then at 50 to 70°C for 0.5 to 20 hours, while keeping the reaction vessel sealed; (c) amplifying a part or all of the region of the transcription regulatory region and / or the region of the transcription start site +1 to +1000 of the gene to be measured using the DNA treated with the restriction enzyme in step (b) as a template; (d) measuring the CpG methylation level in the DNA of the transcription regulatory region and / or the region of the transcription start site +1 to +1000 of the gene to be measured based on the results of the amplification in step (c);a method for measuring the methylation level of CpG in the region +1 to +1000 of the transcription regulatory region and / or transcription start site of a gene to be measured, comprising steps (a) to (d), characterized in that the DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start site that is the target of amplification in step (c) contains one or more sequences recognized by the restriction enzyme used in step (a); and a method for assisting in the diagnosis of hepatocellular carcinoma, hereinafter also referred to as "the present method for assisting in the diagnosis of hepatocellular carcinoma", characterized in that the DNA is measured by the above steps (a) to (d).
[0021] <Body fluids collected from subjects> The subject in this specification is not particularly limited as long as it is a human, and can include, for example, a subject whose cancer status is unknown. Such subjects also include subjects who have previously suffered from cancer and have since recovered from the cancer, but whose cancer status is unknown at the time of testing. In addition, body fluids can include serum, plasma, blood, saliva, urine, etc.
[0022] Serum is generally used in blood biochemistry tests. Plasma, on the other hand, is limited to coagulation system tests and blood glucose tests. Plasma samples are also commonly used in liquid biopsies, including methylation analysis. This is because using serum destroys white blood cells during the coagulation process, increasing white blood cell-derived DNA in the serum and potentially affecting liquid biopsy measurements. When whole blood is used as a liquid biopsy sample to extract DNA, the majority of DNA is white blood cell-derived, resulting in the relative dilution of tumor-derived DNA, making it difficult to detect tumor-derived DNA. For this reason, whole blood samples are not optimal for liquid biopsies. In this method for assisting the diagnosis of hepatocellular carcinoma, if serum is used as the body fluid, a single serum collection tube can be used for blood biochemistry tests and methylation analysis, AFP, and PIVKA-II tests for the diagnosis of hepatocellular carcinoma during health checkups. In health checkups, serum is generally used for blood biochemistry tests. On the other hand, plasma samples are commonly used in liquid biopsies, including methylation analysis for cancer diagnosis. In other words, when attempting to diagnose cancer during a health checkup using conventional methods, two blood collection tubes—one for serum and one for plasma—are required, resulting in a large volume of blood being collected, which places a significant physical and mental burden on the subject. However, by using serum as the sample for methylation analysis, both biochemical testing and methylation analysis can be performed using a single collection tube. Furthermore, because only a small volume of blood is required, this reduces the burden on the subject and also reduces the workload of hospitals that collect blood from many subjects at once.
[0023] For analyzing all indicators, about 0.001 to 10 mL of body fluid can be used, and may be 0.01 to 2 mL, 0.03 to 1 mL, 0.04 to 0.5 mL, 0.05 to 0.3 mL, 0.07 to 0.2 mL, or 0.08 to 0.1 mL. Because the method for assisting in the diagnosis of hepatocellular carcinoma does not require bisulfite treatment, it is possible to diagnose hepatocellular carcinoma with a small amount of body fluid.
[0024] <Indicators> The at least two indicators (A) and (B) include the following four combinations: CpG methylation level and AFP level in DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start point of the SEPT9 gene; CpG methylation level and AFP level in DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start point of the HOXA1 gene; CpG methylation level and PIVKA-II level in DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start point of the SEPT9 gene; CpG methylation level and PIVKA-II level in DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start point of the HOXA1 gene;
[0025] Three indicators may be used as at least the two indicators (A) and (B), and the following four combinations may be used: CpG methylation level, AFP level, and PIVKA-II level in DNA of the transcriptional regulatory region and / or the region +1 to +1000 of the transcription start site of the SEPT9 gene; CpG methylation level, AFP level, and PIVKA-II level in DNA of the transcriptional regulatory region and / or the region +1 to +1000 of the transcription start site of the HOXA1 gene; CpG methylation level in DNA of the transcriptional regulatory region and / or the region +1 to +1000 of the transcription start site of the SEPT9 gene, CpG methylation level in DNA of the transcriptional regulatory region and / or the region +1 to +1000 of the transcription start site of the HOXA1 gene, and AFP level; CpG methylation level in the DNA of the transcriptional regulatory region and / or the region +1 to +1000 of the transcriptional start site of the SEPT9 gene, CpG methylation level in the DNA of the transcriptional regulatory region and / or the region +1 to +1000 of the transcriptional start site of the HOXA1 gene, and PIVKA-II level;
[0026] Four indicators may be used as at least the two indicators (A) and (B), and examples thereof include a combination of the CpG methylation level in DNA in the region of +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the SEPT9 gene, the CpG methylation level in DNA in the region of +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the HOXA1 gene, the AFP level, and the PIVKA-II level.
[0027] Furthermore, by using the CpG methylation level in DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start point of the SEPT9 gene or the CpG methylation level in DNA in the region +1 to +1000 of the transcription regulatory region and / or transcription start point of the HOXA1 gene as an indicator of methylation level, it becomes possible to diagnose hepatocellular carcinoma without analyzing other methylation markers such as EMX1 and TSPYL5.
[0028] <Statistical Analysis> In statistical analysis, examples of multivariate analysis include logistic regression analysis, linear discriminant analysis, and multiple regression analysis. Furthermore, for continuous variables, examples of two-group tests include the Mann-Whitney U test, for multiple comparisons include the Kruskal-Wallis test and Dunn's test, and for categorical variable tests, examples include the chi-square test and Fisher's exact test. Indicators used in statistical analysis may include gender, age, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, platelet count, and other indicators required for the FIB-4 index. Furthermore, the AFP level, PIVKA-II level, CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the SEPT9 gene, and / or CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the HOXA1 gene may be logarithmically or power-transformed, and a normally distributed value may be used, or a binarized value based on a predetermined cutoff value may be used.
[0029] The combination of values to be normally distributed is not particularly limited, and specific examples include the following: When only one indicator is normally distributed, only one of the following indicators can be normally distributed: AFP level, PIVKA-II level, CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the SEPT9 gene, or CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the HOXA1 gene. When two indicators are normally distributed, the following two indicators can be normally distributed: AFP level and PIVKA-II level; AFP level and CpG methylation level in DNA in the region of +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the SEPT9 gene; AFP level and CpG methylation level in DNA in the transcriptional regulatory region of the HOXA1 gene; PIVKA-II level and CpG methylation level in DNA in the region of +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the SEPT9 gene; and PIVKA-II level and CpG methylation level in DNA in the region of +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the HOXA1 gene. When the three indices are normally distributed, the AFP level, the PIVKA-II level, and the CpG methylation level in the DNA of the transcriptional regulatory region and / or the transcriptional start site of the SEPT9 gene in the region +1 to +1000; the AFP level, the PIVKA-II level, and the CpG methylation level in the DNA of the transcriptional regulatory region and / or the transcriptional start site of the HOXA1 gene in the region +1 to +1000; the PIVKA-II level, the transcriptional regulatory region and / or the transcriptional start site of the SEPT9 gene in the region +1 to +1000 The three indices can be normally distributed: the CpG methylation level in DNA, and the CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start site of the HOXA1 gene; or the AFP level, the CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start site of the SEPT9 gene, and the CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start site of the HOXA1 gene.When four indices are normally distributed, the four indices, AFP level, PIVKA-II level, CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the SEPT9 gene, and CpG methylation level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the HOXA1 gene, can be normally distributed.
[0030] When logistic regression analysis is performed as the statistical analysis, for example, when the predicted value (P: Predicted Value) is calculated based on sex, age, normally distributed AFP level (norm_AFP), normally distributed PIVKA-II level (norm_PIVKA-II), and normally distributed CpG methylation level (norm_mSEPT9) in DNA in the region of +1 to +1000 of the transcription regulatory region and / or transcription start site of the SEPT9 gene, the calculation can be made based on the following formula (I):
[0031]
[0032] In the above formula (I), β0 is the intercept (constant term), β1 to β5 are regression coefficients, Sex is gender (substitute 1 for female and 0 for male), Age is age, norm_APF is a normally distributed AFP value, norm_PIVKA-II is a normally distributed PIVKA-II value, and norm_mSEPT9 is a normally distributed methylated SEPT9 value. "norm" means that it is normally distributed.
[0033] Furthermore, for example, when the predicted value is calculated based on sex, age, normally distributed AFP level (norm_AFP), normally distributed PIVKA-II level (norm_PIVKA-II), and normally distributed CpG methylation level (norm_mHOXA1) in DNA in the region of +1 to +1000 of the transcription regulatory region and / or transcription start site of the HOXA1 gene, the calculation can be made based on the following formula (II):
[0034]
[0035] In the above formula (II), β0 is the intercept (constant term), β1 to β5 are regression coefficients, Sex is gender (substitute 1 for female and 0 for male), Age is age, norm_APF is a normally distributed AFP value, norm_PIVKA-II is a normally distributed PIVKA-II value, and norm_mHOXA1 is a normally distributed methylated HOXA1 value. As above, norm means that the distribution is normal.
[0036] <Diagnosis of Hepatocellular Carcinoma> When the above-mentioned predicted value is used to assist in the diagnosis of hepatocellular carcinoma in a subject, a statistical analysis is performed based on at least the two indices (A) and (B) in the body fluid collected from the subject. The closer the value (predicted value) obtained by the statistical analysis is to 1, the higher the possibility of "liver cancer being present," while the closer the predicted value is to 0, the higher the possibility of "liver cancer not being present." Therefore, hepatocellular carcinoma can be diagnosed based on this value (predicted value). Furthermore, in aiding in the diagnosis of hepatocellular carcinoma in a subject, a statistical analysis is performed based on at least two indices (A) and (B) collected from the subject, and the value obtained by the statistical analysis is compared with the value obtained by the statistical analysis in a control subject not suffering from hepatocellular carcinoma. If the value obtained by the statistical analysis based on at least two indices (A) and (B) for the subject is higher than the value obtained by the statistical analysis in the control subject not suffering from hepatocellular carcinoma, the subject can be evaluated as having a high probability of having hepatocellular carcinoma, and if the compared value is lower, the subject can be evaluated as having a low probability of having hepatocellular carcinoma. When making a diagnosis, the value obtained by the statistical analysis in the control subject can be a value measured each time, or a value analyzed in advance. Furthermore, it is preferable that the body fluids of the subject and control subject to be compared are prepared by substantially the same method or obtained by substantially the same measurement method.
[0037] In order to evaluate whether the value obtained by statistical analysis based on at least the two indicators (A) and (B) in the body fluid collected from the subject is higher or lower than the value obtained by the statistical analysis in a control subject not suffering from hepatocellular carcinoma, an arbitrary cutoff value (threshold value) can be appropriately set. Examples of such cutoff values include the mean value, the mean value ± standard deviation (SD), the mean value ± 2SD, the mean value ± 3SD, the median, the median value ± SD, the median value ± 2SD, and the median value ± 3SD of the "value obtained by the statistical analysis in the control subject." Furthermore, to increase the sensitivity (the proportion of subjects with cancer who can be correctly judged as positive) and specificity (the proportion of subjects without cancer who can be correctly judged as negative), the cutoff value can be calculated using the Youden Index or the like by creating an ROC (Receiver Operating Characteristic) curve using statistical analysis software based on the data of "values obtained by statistical analysis based on the two indices (A) and (B) in the body fluid collected from the subject" and the data of "values obtained by statistical analysis based on the two indices (A) and (B) in the body fluid collected from the control subject."
[0038] <Hepatocellular carcinoma> Hepatocellular carcinoma also includes early stage hepatocellular carcinoma. Early stage hepatocellular carcinoma refers to hepatocellular carcinoma at stage 0 or A according to the BCLC staging system (Barcelona Clinical Liver Cancer Staging System) described in Non-Patent Document 4 above.
[0039] <Measurement of AFP and PIVKA-II> AFP levels and PIVKA-II levels can be measured by known techniques, such as enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassay (FIA), chemiluminescent immunoassay (CLIA), chemiluminescent enzyme immunoassay (CLEIA), and immunochromatography.
[0040] As used herein, CpG methylation refers to a state in which a methyl group is attached to the carbon atom at the 5th position of the cytosine (C) residue in a CpG sequence, which is a two-base sequence (dinucleotide) in DNA in which a guanine (G) base appears next to a cytosine (C) base. Here, the "p" represents the phosphodiester bond between cytosine and guanine.
[0041] The CpG methylation level herein can be evaluated by amplifying a specific region of DNA encoding the gene to be measured to obtain DNA fragments, and then measuring the number of DNA fragments (copy number) in which cytosines in the CpGs are methylated. Specifically, examples include the copy number per unit volume (e.g., per μL) of the solution treated with the restriction enzyme in step (c), the copy number per total volume of the solution treated with the restriction enzyme in step (c), the copy number per unit volume of the DNA source sample (e.g., per mL of serum), and the ratio of methylated DNA to an internal control. The internal control may be any human DNA that does not have a cleavage site for a methylation-sensitive restriction enzyme within the PCR-amplified region, such as human TERT or RNase P.
[0042] As used herein, the term "transcriptional regulatory region of a gene" refers to a region containing a nucleic acid sequence to which a transcriptional regulatory factor binds and which regulates the amount of transcription of the gene. This transcriptional regulatory region includes promoter regions, enhancer regions, suppressor regions, etc.
[0043] As used herein, the transcription start point refers to the site where transcription of mRNA starts, and corresponds to the position corresponding to the first base of mRNA. In this specification, the transcription start point is represented as "+1," and the position one base upstream of the transcription start point is represented as "-1." Therefore, +1000 of the transcription start point means a position 999 bases downstream when the transcription start point is represented as +1.
[0044] In addition, the region from +1 to +1000 of the transcription start point in this specification includes exons and introns within the region from +1 to +1000 of the transcription start point, and examples of exons include exon 1, exon 2, and exon 3, and examples of introns include intron 1 and intron 2. Furthermore, examples of the region from +1 to +1000 of the transcription start point include the region from +1 to +500 of the transcription start point, the region from +1 to +350 of the transcription start point, the region from +1 to +100 of the transcription start point, and the region from +1 to +60 of the transcription start point.
[0045] Furthermore, the transcription regulatory region and / or the region between +1 and +1000 from the transcription start point herein can refer to a region between +1 and +1000 from the transcription start point and 100 bases upstream to 100 bases downstream of the adenine (A) of the start codon, preferably 50 bases upstream to 50 bases downstream of the start codon. Here, the start codon refers to the codon that serves as the initiation point for protein synthesis when mRNA is translated into protein.
[0046] <Step (a)> The reaction vessel used herein is not particularly limited as long as it is a vessel that can be treated with a restriction enzyme and is sealable. Here, "sealed" refers to a state in which the liquid in the reaction vessel cannot leak out, and "sealing" can refer to, for example, putting a lid on a vessel that contains a liquid, such as a microtube.
[0047] The gene to be measured in this specification is not particularly limited as long as it contains one or more sequences recognized by the restriction enzyme used in step (a) in the transcriptional regulatory region and / or the region from +1 to +1000 of the transcription start site of the gene. That is, the recognition sequences are four-base HhaI (GCG / C), HpaII (C / CGG), and BstUI (CG / CG), the recognition sequence is five-base Hpy99I (CGWCG / ), the recognition sequence is five-base SacII (CCGC / GG), SmaI (CCC / GGG), AatII (GACGT / C), AccI (GT / MKAC), Aor13HI (T / CCGGA), Aor51HI (AGC / GCT), BspT104I (TT / CGAA), BssHII (G / CGCGC), Cfr10I (R / CCGGY), ClaI (AT / CGAT), and Eco52I (C / G Examples of such a gene include a gene containing at least one sequence recognized by at least one, and preferably two, methylation-sensitive restriction enzymes selected from the group consisting of HaeII (RGCGC / Y), MluI (A / CGCGT), NaeI (GCC / GGC), NruI (G / CTAGC), PmaCI (CAC / GTG), Psp1406I (AA / CGTT), PvuI (CGAT / CG), SalI (G / TCGAC), SnaBI (TAC / GTA), CpoI (CG / GWCCG) having a 7-base recognition sequence, and NotI (GC / GGCCGC) having an 8-base recognition sequence. Furthermore, the transcriptional regulatory region and / or the region from +1 to +1000 of the transcription start site of the gene may contain one or more, preferably one or two, sequences recognized by the restriction enzyme described in step (a)(ii) and one or more, preferably one, sequence recognized by BstUI. Here, "W" above means A or T, "M" means A or C, "K" means G or T, "R" means A or G, and "Y" means C or T.
[0048] Specific examples of the genes to be measured include the SEPT9 gene, HOXA1 gene, SST gene, RUNX3 gene, ADAMTS2 gene, PCDH10 gene, SEMA5A gene, SPSB4 gene, BMP3 gene, NDRG4 gene, and SDC2 gene, which are genes whose CpG methylation levels in DNA in the transcriptional regulatory region and / or the region between +1 and +1000 of the transcription start site in a subject fluctuate depending on the presence of cancer.
[0049] The DNA containing the gene to be measured can be obtained by extraction from the body fluid, preferably serum. Methods for extracting DNA from body fluids include phenol extraction, phenol-chloroform extraction, alkaline lysis, and methods using commercially available DNA extraction reagents.
[0050] Restriction enzymes to be added to the reaction vessel include (ii) at least one, preferably two or more, more preferably two restriction enzymes selected from HhaI, HpaII, Hpy99I, SacII, SmaI, NotI, AatII, AccI, Aor13HI, Aor51HI, BspT104I, BssHII, Cfr10I, ClaI, CpoI, Eco52I, HaeII, MluI, NaeI, NruI, PmaCI, Psp1406I, PvuI, SalI, and SnaBI, and (iii) BstUI. Note that BstUI is also sold under the names AccII, Bsh1236I, BspFNI, BstFNI, FnuDII, or MvnI depending on the manufacturer of the restriction enzyme.
[0051] The restriction enzyme is a methylation-sensitive restriction enzyme. A methylation-sensitive restriction enzyme is a restriction enzyme that can distinguish between methylated and unmethylated CpGs in a sequence recognized by the restriction enzyme. Methylation-sensitive restriction enzymes are used in methods for analyzing CpG methylation, utilizing the phenomenon that methylation of cytosines in a sequence recognized by a restriction enzyme makes it unable to cleave DNA. Preferred combinations of the restriction enzymes include two types of restriction enzymes, HhaI and BstUI, HpaII and BstUI, and three types of restriction enzymes, HhaI, HpaII and BstUI. It is preferable to use heat-inactivated BstUI, specifically BstUI that remains active even after treatment at 65°C for 20 minutes (or 60°C for 1 hour).
[0052] When treating with the methylation-sensitive restriction enzyme, if single-stranded DNA is present in the template DNA, the single-stranded DNA will avoid cleavage by the restriction enzyme and will be amplified in the subsequent PCR reaction, resulting in false positives. To avoid this, it is preferable to add exonuclease I (ExoI) to remove the single-stranded DNA. Furthermore, when treating with the methylation-sensitive restriction enzyme, from the viewpoint of efficient PCR amplification, a restriction enzyme that cannot cleave the base sequence in the amplification target region, including CpG, may also be added to fragment the DNA.
[0053] The restriction enzyme reaction buffer may be any buffer that can cleave DNA by the enzymatic reaction of the restriction enzyme used, and can be selected appropriately depending on the restriction enzyme used. In addition to commercially available restriction enzyme reaction buffers, buffers for PCR can also be used.
[0054] <Step (b)> Step (b) is a step of performing restriction enzyme treatment. The treatment with the restriction enzyme involves two temperature stages. The treatment temperature in the first stage can be adjusted as appropriate, but is, for example, within the range of 30 to 50°C, preferably within the range of 35 to 40°C, and more preferably within the range of 36 to 38°C. The treatment time in the first stage can be adjusted as appropriate, but is, for example, within the range of 0.5 to 16 hours, preferably 0.7 to 8 hours, more preferably 0.9 to 4 hours, and even more preferably 1 to 2 hours.
[0055] The treatment temperature in the second stage can be adjusted as appropriate, but is, for example, within a range of 50 to 70° C., preferably within a range of 55 to 65° C., and more preferably within a range of 58 to 62° C. The treatment time in the second stage can be adjusted as appropriate, but is, for example, within a range of 0.5 to 20 hours, preferably within a range of 6 to 18 hours, more preferably within a range of 12 to 17 hours, and even more preferably within a range of 14 to 16 hours.
[0056] In the above-mentioned restriction enzyme treatment, the first and second stages are performed consecutively while the reaction vessel is sealed. In other words, the second stage is performed without opening the lid of the reaction vessel after the first stage, without releasing the sealed state. In conventional methods, such as the method described in Patent Document 2, the lid of the reaction vessel is opened after the first stage, a restriction enzyme is added, the lid is closed and sealed, and the second stage is performed. Therefore, the process of adding the restriction enzyme in the second stage is cumbersome and requires time and effort. Furthermore, there is also the problem of the liquid in the reaction vessel evaporating, changing the composition within the reaction vessel. On the other hand, in the above-mentioned method for measuring CpG methylation levels, all of the restriction enzymes are added to the reaction vessel at once, so there is no need to open the lid of the reaction vessel after the first stage.
[0057] <Step (c)> In step (c), the DNA treated with the restriction enzyme in step (b) is used as a template to amplify part or all of the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the gene to be measured (SEPT9 gene and / or HOXA1 gene). The part or all of the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the gene to be measured to be amplified may be a region containing at least one sequence recognized by the restriction enzyme used in step (a), and may be a region containing one to four sequences, preferably one to three sequences. Furthermore, in the part or all of the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the gene to be amplified, there may be one, two, three, or four sequences recognized by the same methylation-sensitive restriction enzyme used in step (a). Furthermore, when two or more restriction enzymes are used in step (a), one of the restriction enzymes may recognize only one sequence, or one sequence may be recognized by one type of restriction enzyme and two or more, preferably two, sequences may be recognized by the other type of restriction enzyme. In addition, the region to be amplified may be part of the transcription regulatory region of the gene to be measured and part of the region from +1 to +1000 of the transcription start site, only part of the transcription regulatory region of the gene to be measured, only part of the region from +1 to +1000 of the transcription start site of the gene to be measured, or part of the transcription regulatory region and part of the region of exon 1 of the gene to be measured.
[0058] The length of part or all of the transcription regulatory region and / or the region from +1 to +1000 of the transcription start site of the gene to be measured to be amplified can be 30 to 1000 bases, preferably 40 to 200 bases, more preferably 50 to 150 bases.
[0059] When two or more restriction enzymes are used in step (a), the region of the transcription regulatory region and / or the region from +1 to +1000 of the transcription start site of the gene to be amplified may not contain a sequence recognized by at least one of the restriction enzymes used in step (a). For example, three restriction enzymes, X, Y, and Z, may be used in step (a), and the region of the transcription regulatory region and / or the region from +1 to +1000 of the transcription start site of the gene to be amplified may contain sequences recognized by restriction enzymes X and Y at one or more independent locations, respectively, but may not contain a sequence recognized by restriction enzyme Z. In the above example, restriction enzyme Z is thought to be unnecessary because it has no effect on methylation measurement. However, even a small amount of DNA cleavage in the restriction enzyme treatment in step (b) can improve PCR amplification efficiency, which is ultimately useful for methylation measurement.
[0060] The method for amplifying part or all of the transcriptional regulatory region and / or the region between +1 and +1000 of the transcription start site of the gene to be measured is not particularly limited, and examples include PCR methods such as digital PCR (polymerase chain reaction) and real-time PCR; and LAMP (Loop-Mediated Isothermal Amplification).
[0061] The "digital PCR" method is a method for absolute quantification of sample DNA. In this method, sample DNA is compartmentalized (diluted and distributed) into approximately 20,000 droplets or wells, and PCR is performed using a thermal cycler. Droplets or wells containing target DNA glow, while those without do not. The principle is that by counting the number of glowing and non-glowing droplets or wells, the concentration of the gene being measured in the sample can be calculated as an absolute value. The data is determined by the presence or absence of target DNA in the droplets or wells, which is equivalent to a digital signal of 1 / 0, hence the name "digital PCR." Furthermore, "copy number counting" in digital PCR refers to the process of measuring the fluorescence intensity of each of the approximately 20,000 droplets or wells using a droplet reader, counting the number of fluorescent droplets or wells and those with weak fluorescence intensity, and then calculating the absolute value of the gene copy number using correction using a Poisson model.
[0062] Specifically, the digital PCR is performed as follows: (1) A PCR reaction solution containing template DNA is compartmentalized into approximately 20,000 droplets (small droplets). (2) Approximately 20,000 droplets are collected in one tube. (3) A PCR reaction is performed (PCR is performed on approximately 20,000 droplets per tube). (4) The fluorescence intensity of each of the approximately 20,000 droplets is measured, and the number of droplets with high and low fluorescence intensities is counted. The copy number of the target gene in the sample is calculated by correction using a Poisson model. Here, a high fluorescence intensity of a certain droplet means that the target gene is contained in that droplet and that the fluorescence intensity has increased due to PCR amplification.
[0063] Examples of the PCR method include the TaqMan probe method, the intercalator method, the 5'-nuclease method, and the cycling probe method.
[0064] When the gene to be measured is the SEPT9 gene, a specific example of part or all of the region from +1 to +1000 of the transcription regulatory region and / or transcription start site of the SEPT9 gene is the sequence of the region from the transcription start site (position 75,369,272 on human chromosome 17) to +295 to +356 of SEPT9 gene transcript variant 2 (positions 75,369,566 to 75,369,627 on human chromosome 17 according to position information in the GRCh37 / hg19 database: SEQ ID NO: 1). The sequence of the +295 to +356 region corresponds to the exon 1 region. Furthermore, when the gene to be measured is the SEPT9 gene, examples of the cytosine of CpG for which the methylation level is measured in part or all of the region between +1 and +1000 of the transcription regulatory region and / or transcription start site of the SEPT9 gene include cytosines at positions 75,369,591, 75,369,593, 75,369,600, and 75,369,602 of human chromosome 17 (cytosines at positions 26, 28, 35, and 37 in SEQ ID NO: 1), positions 75,369,591 and 75,369,593 of human chromosome 17, positions 75,369,591 and 75,369,600 of human chromosome 17, positions 75,369,591 and 75,369,602 of human chromosome 17, two cytosines at positions 75,369,593 and 75,369,600 on human chromosome 17, two cytosines at positions 75,369,593 and 75,369,602 on human chromosome 17, two cytosines at positions 75,369,600 and 75,369,602 on human chromosome 17, two cytosines at positions 75,369,591, 75,369,593, and 75,369,600 on human chromosome 17, two cytosines at positions 75,369,591, 75,369,593, and 75,369,602 on human chromosome 17, two cytosines at positions 75,369,591, 75,369,593, and 75,369,602 on human chromosome 17, two cytosines at positions 75,369,591, 75,369,600, and 75,369,602 on human chromosome 17, The amino acid sequence may be three cytosines at positions 75,369,593, 75,369,600, and 75,369,602 of human chromosome 17, or four cytosines at positions 75,369,591, 75,369,593, 75,369,600, and 75,369,602 of human chromosome 17.
[0065] When the gene to be measured is the HOXA1 gene, a specific example of part or all of the region from +1 to +1000 of the transcription regulatory region and / or transcription start site of the HOXA1 gene is the sequence from the transcription start site of the HOXA1 gene (position 27,096,000 on human chromosome 7) to the region from +20 to +127 (positions 27,095,874 to 27,095,981 on human chromosome 7 according to the location information in the GRCh38 / hg38 database: SEQ ID NO: 2). The sequence of the +20 to +127 region corresponds to the exon 1 region. Furthermore, when the gene to be measured is the HOXA1 gene, an example of the cytosine of the CpG for which the methylation level is measured in part or all of the region from +1 to +1000 of the transcription regulatory region and / or transcription start site of the HOXA1 gene is the cytosine at position 27,095,945 of human chromosome 7 in the exon 1 region (the 37th cytosine in SEQ ID NO: 2).
[0066] The primers for amplifying part or all of the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the gene to be measured, and the probe for detecting the amplified nucleic acid, may be primer sets, probes, or labeled versions thereof for individually measuring the methylation of each cytosine of the CpG to be measured contained in part or all of the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the gene to be measured, but it is preferable to use primer sets, probes, or labeled versions thereof for commonly measuring the methylation of each cytosine of the CpG to be measured in the DNA of part or all of the region +1 to +1000 of the transcription regulatory region and / or transcription start site to be amplified. Specifically, for example, when two CpGs to be measured are contained in part or all of the region +1 to +1000 of the transcription regulatory region and / or transcription start site of the gene to be measured, amplification may be performed using two pairs of primers for amplifying each CpG individually, or one pair of primers that can amplify two CpGs at once. The probes may be two probes that hybridize to the base sequences of the respective PCR amplified regions, or one probe that hybridizes to the base sequences of both PCR amplified regions. Note that the CpG in steps (c) and (d) above is a CpG in a sequence recognized by at least one of the restriction enzymes used in step (a).
[0067] When the gene to be measured is SEPT9, suitable examples include a forward primer consisting of the nucleic acid sequence shown in SEQ ID NO: 3, or a forward primer consisting of the nucleic acid sequence shown in SEQ ID NO: 3, in which one or several nucleic acids have been substituted, deleted, inserted, or added; a reverse primer consisting of the nucleic acid sequence shown in SEQ ID NO: 4, or a reverse primer consisting of the nucleic acid sequence shown in SEQ ID NO: 4, in which one or several nucleic acids have been substituted, deleted, inserted, or added; a probe consisting of the nucleic acid sequence shown in SEQ ID NO: 5, or a probe consisting of the nucleic acid sequence shown in SEQ ID NO: 5, in which one or several nucleic acids have been substituted, deleted, inserted, or added; and these labeled products.
[0068] When the gene to be measured is HOXA1, suitable examples include a forward primer consisting of the nucleic acid sequence shown in SEQ ID NO: 6, or a forward primer consisting of the nucleic acid sequence shown in SEQ ID NO: 6, in which one or several nucleic acids have been substituted, deleted, inserted, or added; a reverse primer consisting of the nucleic acid sequence shown in SEQ ID NO: 7, or a reverse primer consisting of the nucleic acid sequence shown in SEQ ID NO: 7, in which one or several nucleic acids have been substituted, deleted, inserted, or added; a probe consisting of the nucleic acid sequence shown in SEQ ID NO: 8, or a probe consisting of the nucleic acid sequence shown in SEQ ID NO: 8, in which one or several nucleic acids have been substituted, deleted, inserted, or added; and labeled products thereof.
[0069] The above-mentioned "nucleic acid sequence in which one or several nucleic acids have been substituted, deleted, inserted, or added" means a nucleic acid sequence in which, for example, 1 to 5, preferably 1 to 3, more preferably 1 to 2 nucleic acids have been substituted, deleted, inserted, or added.
[0070] Examples of the labeling substances for the forward primer label, the reverse primer label, and the probe label include enzymes such as peroxidase (e.g., horseradish peroxidase), alkaline phosphatase, β-D-galactosidase, glucose oxidase, glucose-6-phosphate dehydrogenase, alcohol dehydrogenase, malate dehydrogenase, penicillinase, catalase, apoglucose oxidase, urease, luciferase, and acetylcholinesterase; fluorescent substances such as fluorescein isothiocyanate, phycobiliprotein, rare earth metal chelates, dansyl chloride, and tetramethylrhodamine isothiocyanate; green fluorescent protein (GFP), cyan fluorescent protein (CFP), blue fluorescent protein (BFP), yellow fluorescent protein (YFP), red fluorescent protein (Red Fluorescent Protein), and the like. Examples of reporter fluorescent substances include fluorescent proteins such as radioisotopes (RFP), luciferase, and the like; radioisotopes such as 3H, 14C, 125I, and 131I; biotin, avidin, or chemiluminescent substances; and combinations of reporter fluorescent substances and quencher substances or structures (for example, a combination of 5-FAM [5-carboxyfluorescein] and 5-TAMRA [5-carboxytetramethylrhodamine], a combination of VIC and MGB [minor groove binder], and a combination of 5-FAM and MGB).
[0071] <Step (d)> In step (d), based on the results of the amplification in step (c), the methylation level of CpGs in the DNA of the transcription regulatory region and / or the region from +1 to +1000 of the transcription start site targeted for amplification in step (c) is measured. Specifically, the methylation level of the CpGs can be measured based on the degree of amplification of DNA that has escaped cleavage by the methylation-sensitive restriction enzyme due to methylation in step (c). The degree of DNA amplification can be evaluated by detecting the amplified DNA using a probe or the like.
[0072] In step (d), "measuring the methylation level of CpGs" may involve not only measuring the methylation of CpGs in the region of +1 to +1000 of the transcription regulatory region and / or transcription start site to be amplified, but also measuring the methylation of the corresponding CpGs in the complementary strand.
[0073] In the above-mentioned method for measuring CpG methylation levels, it is preferable not to perform sodium bisulfite treatment (bisulfite treatment). Bisulfite treatment treats single-stranded DNA, which easily degrades the DNA, resulting in the loss of approximately 90% of the DNA due to denaturation. Since the detection limit of quantitative PCR is approximately 10 copies, sodium bisulfite treatment requires 100 or more copies of target DNA. When quantitatively analyzing absolute copy numbers using quantitative PCR, it is necessary to create a calibration curve using a standard substance, but this poses the problem of extremely low reliability of measurements at low copy numbers. On the other hand, digital PCR does not require the creation of a calibration curve and enables accurate absolute number measurement even at low copy numbers.
[0074] The present invention will be explained in more detail below with reference to examples, but the technical scope of the present invention is not limited to these examples.
[0075] [Example 1] First, in measuring the CpG methylation level, the method described in Patent Document 2 performs restriction enzyme treatment in two stages by adding restriction enzymes. Specifically, in the first stage, two types of restriction enzymes are added to a DNA solution and reacted at 37°C for 16 hours, and then in the second stage, an additional type of restriction enzyme is added and reacted at 60°C for 16 hours. Here, this two-stage restriction enzyme treatment requires the addition of a second-stage restriction enzyme after the first-stage restriction enzyme treatment. For example, when handling 96 samples, the addition of the second-stage restriction enzyme involves the following steps, and performing all of the steps requires approximately 60 minutes. (1) Remove the microtube containing the DNA solution that has been enzyme-treated in the first step from the warmer (2 minutes). (2) Centrifuge the microtube (6 minutes). (3) Open the lid of the microtube (2 minutes). (4) Add the restriction enzyme (BstUI) in the second step (10 seconds x 96 = 960 seconds = 16 minutes). (5) Pipette approximately 20 times to thoroughly mix the DNA solution and enzyme (15 seconds x 96 = 1440 seconds = 24 minutes). (6) Close the lid of the microtube and seal it (2 minutes). (7) Centrifuge the microtube (6 minutes). (8) Place the microtube in the warmer (2 minutes).
[0076] Therefore, first, we verified whether it is possible to easily measure the CpG methylation level in the transcriptional regulatory region and / or the region between +1 and +1000 of the transcription start site of the gene to be measured by adding a restriction enzyme only once.
[0077] (Preparation of SEPT9 or HOXA1 Methylation Control DNA Sample) As a control for the methylated alleles of SEPT9 and HOXA1, EpiScope Methylated HCT116 gDNA (DNA derived from the human colon cancer cell line HCT116 that is highly methylated by CpG methylase, and is SEPT9 or HOXA1 methylation control DNA), which is known to have high levels of methylation in various genes including SEPT9 and HOXA1, was used.
[0078] (Preparation of SEPT9 or HOXA1 Unmethylated Control DNA Samples) DNA derived from peripheral blood lymphocytes (SEPT9 unmethylated control DNA or HOXA1 unmethylated control DNA), known to have little or no methylation of SEPT9 or HOXA1, was used as a control for the SEPT9 or HOXA1 unmethylated allele. Peripheral blood was collected using a blood collection tube containing the anticoagulant EDTA-2Na, and 0.2% NaCl was added. The blood was mixed by inversion and then centrifuged at 2500 rpm for 5 minutes. The supernatant was removed using an aspirator to avoid absorbing the leukocytes that had settled at the bottom of the tube. This procedure was repeated until the pellet (leukocytes) turned white. The white pellet was transferred to a 1.5 mL tube, and nucleic acid extraction was performed using the nucleic acid extraction agent SepaGene (Sanko Junyaku Co., Ltd.). The extraction method followed the instructions for use. The nucleic acid pellet obtained by extraction was air-dried and dissolved in 100 μL of TE buffer to prepare a SEPT9 unmethylated control DNA or HOXA1 unmethylated control DNA sample.
[0079] Next, methylated control DNA (EpiScope Methylated HCT116 gDNA) was added to a fixed concentration (0.8 ng / μL) of unmethylated control DNA to prepare a dilution series of methylated control DNA samples: 0%, 3.1%, 6.3%, 12.5%, 25%, 50%, and 100%.
[0080] Table 1 shows the relationship between the concentration and dilution series (%) of the methylation control DNA (SEPT9 methylation control or HOXA1 methylation control) added to each sample.
[0081]
[0082] (Enzyme Treatment) Next, an enzyme treatment containing a methylation-sensitive restriction enzyme was carried out under the following two conditions: Condition 2 is the method described in Patent Document 1 above.
[0083] <Condition 1: Single Treatment> One-step enzyme treatment of DNA: simultaneous treatment with HhaI, HpaII, ExoI, and BstUI 1. Place 10 μL of the DNA sample prepared in Table 1 into a 1.5 mL tube. 2. Add 1 μL of AmpliTaq Gold buffer II (included in AmpliTaq Gold DNA Polymerase Kit N808-0241: Thermo Fisher Scientific). 3.25 mM MgCl 2 3. Add 1 μL of solution (supplied with AmpliTaq Gold DNA Polymerase Kit N808-0241: Thermo Fisher Scientific). 4. Add 1 μL (10 U) of HhaI (Thermo Fisher Scientific). 5. Add 1 μL (10 U) of HpaII (Thermo Fisher Scientific). 6. Add 1 μL (20 U) of ExoI (Thermo Fisher Scientific). 7. Add 1 μL (10 U) of BstUI (New England BioLabs). 8. Mix by pipetting and then close the tube lid to seal. 9. Heat at 37°C for 1 hour. 10. Heat at 60°C for 16 hours. 11. Heat at 98°C for 10 minutes.
[0084] <Condition 2: Two-step treatment> Two-step enzyme treatment of DNA: Treatment with HhaI, HpaII, and ExoI, followed by BstUI treatment. 1. Place 10 μL of the DNA sample prepared in Table 1 into a 1.5 mL tube. 2. Add 1 μL of AmpliTaq Gold buffer II (included in AmpliTaq Gold DNA Polymerase Kit N808-0241: Thermo Fisher Scientific). 3.25 mM MgCl 2Add 1 μL of solution (supplied with AmpliTaq Gold DNA Polymerase Kit N808-0241: Thermo Fisher Scientific). 4. Add 1 μL (10 U) of HhaI (Thermo Fisher Scientific). 5. Add 1 μL (10 U) of HpaII (Thermo Fisher Scientific). 6. Add 1 μL (20 U) of ExoI (Thermo Fisher Scientific). 7. Mix by pipetting, then close the tube lid and seal. 8. Heat at 37°C for 16 hours. 9. Open the tube cap and add 1 μL (10 U) of BstUI (New England BioLabs), then seal the tube. 10. Heat at 60°C for 16 hours. 11. Heat at 98°C for 10 minutes.
[0085] The above-mentioned HhaI, HpaII, and BstUI are methylation-sensitive restriction enzymes that recognize and cleave the base sequence 5'-GCGC-3', 5'-CCGG-3', and 5'-CGCG-3', respectively. If the cytosine of the CpG in this base sequence is methylated, this base sequence remains uncleaved, allowing it to be amplified by PCR later.
[0086] Table 2 shows the base sequences of the regions to be amplified by PCR. In Table 2, the underlined bases in the base sequence column for the region to be amplified by PCR indicate sites that may be cleaved by the restriction enzymes HhaI, HpaII, or BstUI. However, because these restriction enzymes are methylation-sensitive restriction enzymes, if the cytosine (C) of the underlined CG in Table 2 is methylated, the recognition site of the restriction enzyme containing the methylated cytosine will not be cleaved. Furthermore, each amplified region is part of the exon 1 region. In the NCBI Reference Sequence Database, the RefSeq for SEPT9 mRNA is NM_001113493 (updated June 14, 2013), and the RefSeq for HOXA1 mRNA is NM_005522 (updated February 17, 2023) or NM_153620 (updated February 17, 2023). In this specification, the transcription start site of HOXA1 is represented based on NM_005522.
[0087]
[0088] (Digital PCR Processing) As mentioned above, "digital PCR" is a method for absolutely quantifying the amount of DNA in a sample. Here, a digital PCR system (QX200 Droplet Digital PCR System: Bio-Rad) was used.
[0089] After the enzyme reaction was completed, 2 μL of the enzyme-reacted DNA solution treated under Condition 1 or Condition 2 above, 6 μL of water, and 14 μL of PCR reaction solution were mixed to prepare a DNA-containing PCR reaction solution. This DNA-containing PCR reaction solution consisted of 1 μL each of a 20 μM primer mix and a 5 μM probe (4 μL total) for amplifying predetermined regions of the SEPT9 gene and HOXA1 gene and measuring predetermined methylated cytosines, and 10 μL of 2×ddPCR Master Mix (Bio-Rad). Multiplex PCR was performed using the above DNA-containing PCR reaction solution.
[0090] The base sequences of the primers and probe for SEPT9 are as follows: Forward primer: 5'-GCCCACCAGCCATCATGT-3' (SEQ ID NO: 3) Reverse primer: 5'-GTCCGAAATGATCCCATCCA-3' (SEQ ID NO: 4) Probe: 5'-FAM-CCGCGGTCAACGC-MGB-3' (SEQ ID NO: 5)
[0091] The base sequences of the HOXA1 primer and probe are as follows: Forward primer: 5'-CCCATGGAGGAAGTGAGAAA-3' (SEQ ID NO: 6) Reverse primer: 5'-GGGGTATTCCAGGAAGGAGT-3' (SEQ ID NO: 7) Probe: 5'-FAM-GCACAGTCACGCCGG-MGB3' (SEQ ID NO: 8)
[0092] From this DNA-containing PCR reaction solution, an Automated Droplet Generator (Bio-Rad) was used to create droplets (droplets), and using a thermal cycler, the mixture was preheated at 95 ° C. for 10 minutes, followed by 40 cycles of thermal denaturation at 94 ° C. for 30 seconds and annealing at 56 ° C. for 60 seconds to amplify the DNA, and finally heated at 98 ° C. for 10 minutes. After DNA amplification, the fluorescent dye derived from the TaqMan probe in each droplet was detected using a QX200 Droplet Reader (Bio-Rad) and QuantaSoft software (Bio-Rad), and the number of DNA fragments in which cytosine in the CpG of the amplified region of the target gene was methylated, which had escaped cleavage by methylation-sensitive restriction enzymes, was measured (copy number).
[0093] The base sequences (5'-GCGC-3', 5'-CCGG-3', 5'-CGCG-3') containing the underlined CpGs in Table 2 of the DNA in the amplification target region of SEPT9 or HOXA1 can be recognized by any of the three restriction enzymes used (HhaI, HpaII, BstUI). For example, in the case of SEPT9, if the CpGs in 5'-GCGC-3' and / or 5'-CGCG-3' are unmethylated, they are recognized and cleaved by the restriction enzymes HhaI and / or BstUI, and are not amplified by PCR, and therefore are not detected. On the other hand, if all CpGs in 5'-GCGC-3' and 5'-CGCG-3' are methylated, they are prevented from cleavage by the restriction enzymes and are amplified by PCR, and are therefore detected. Therefore, if all cytosines in the CpGs in the base sequences GCGC and CGCG within the PCR amplification target region of SEPT9 in the template DNA shown in Table 2 are methylated, restriction enzyme treatment by a single treatment (condition 1) or a two-step treatment (condition 2) will not result in cleavage of GCGC and CGCG, and the region can be amplified by subsequent PCR, allowing it to be counted as the number of methylated SEPT9 copies by digital PCR. In HOXA1, if the 5'-CCGG-3' CpG is not methylated, it is recognized and cleaved by HpaII and is not amplified by PCR, and therefore is not detected. On the other hand, if the 5'-CCGG-3' CpG is methylated, it escapes cleavage by the restriction enzyme and is amplified by PCR, and is therefore detected. Therefore, if the CpG cytosine in the base sequence CCGG within the HOXA1 PCR amplification target region in the template DNA shown in Table 2 is methylated, restriction enzyme treatment by a single treatment (condition 1) or a two-step treatment (condition 2) will not result in cleavage of CCGG, and the region can be amplified by subsequent PCR, allowing it to be counted as the methylated HOXA1 copy number by digital PCR. Note that the amplified region of SEPT9 contains the BstUI and HhaI cleavage sites but not the HpaII cleavage site, and the amplified region of HOXA1 contains the HpaII cleavage site but not the BstUI and HhaI cleavage sites.
[0094] (Results) Comparison of copy numbers of methylated SEPT9 or methylated HOXA1 due to differences in restriction enzyme treatment Figure 1 shows a graph showing the relationship between the methylated SEPT9 copy number obtained by a single treatment (condition 1) and the methylated SEPT9 copy number obtained by a two-stage treatment (condition 2) for the SEPT9 gene, and Figure 2 shows a graph showing the relationship between the methylated HOXA1 copy number obtained by a single treatment (condition 1) and the methylated HOXA1 copy number obtained by a two-stage treatment (condition 2) for the HOXA1 gene. The horizontal axis shows the copy number of SEPT9 when 0%, 3.1%, 6.3%, 12.5%, 25%, 50%, and 100% methylated control DNA dilution series samples were treated with restriction enzymes under condition 2, and the vertical axis shows the copy number of SEPT9 when treated with restriction enzymes under condition 1. As a result of linear regression analysis, Y=1.08X for FIG. 1 and Y=0.99X for FIG.
[0095] These results confirmed a correlation between restriction enzyme treatment under condition 2 and restriction enzyme treatment under condition 1. Therefore, it was confirmed that the above-described method for measuring CpG methylation levels can easily measure methylation levels at the same level as those obtained by conventional restriction enzyme treatment.
[0096] [Example 2] It was confirmed from Example 1 above that the methylation level can be easily measured by the method under Condition 1. Therefore, it was investigated whether hepatocellular carcinoma can be diagnosed by combining the copy number of methylated SEPT9 or methylated HOXA1 with other hepatocellular carcinoma markers.
[0097] As shown in Table 3, the subjects included 247 control subjects (154 healthy controls and 93 chronic liver injury patients) and 269 hepatocellular carcinoma (HCC) patients. The chronic liver injury patients included 62 with chronic hepatitis (CH) and 31 with liver cirrhosis (LC). The hepatocellular carcinoma (HCC) group included 109 with early hepatocellular carcinoma (BCLC stage 0 / A), 135 with viral hepatocellular carcinoma (HBV, HCV, HBV + HCV), and 134 with non-viral hepatocellular carcinoma (NBNC). The progression of hepatocellular carcinoma was determined using the criteria of the BCLC staging system, with Stage 0 / A being considered early stage hepatocellular carcinoma. Of the 109 patients, 61 had viral hepatocellular carcinoma and 48 had non-viral hepatocellular carcinoma.
[0098]
[0099] (Blood Sample Collection) For the healthy control group (154 healthy controls), subjects who underwent colonoscopy during a medical checkup and did not have a colon tumor were enrolled as the healthy control group. This is because mSEPT9 has been reported to be increased in colon cancer. Blood samples were collected before colonoscopy. Blood samples were collected from the hepatocellular carcinoma patient group before treatment. The collected blood samples were centrifuged at 1200 g for 10 minutes to separate 3-4 mL of serum from 8 mL of blood, which was then dispensed into 2 mL tubes and stored frozen at -20°C.
[0100] (Measurement of AFP Levels) The AFP concentration (ng / mL) in 0.025 mL of serum was measured by EIA. The test reagent used was ST E Test "TOSOH" II (AFP) (Tosoh Corporation), and measurements were taken according to the attached protocol. The measurement device used was AIA-2000 (Tosoh Corporation).
[0101] (Measurement of PIVKA-II Level) The PIVKA-II concentration (mAU / mL AU: arbitrarily unit standard) in 0.025 mL of serum was measured as the PIVKA-II level by EIA. The test reagent used was E-Test "TOSOH" II (PIVKA-II) (Sekisui Medical Co., Ltd.), and measurements were performed according to the attached protocol. The measurement device used was AIA-2000 (Tosoh Corporation).
[0102] (DNA Extraction) The frozen serum samples were thawed, and DNA was extracted from 1.0 mL of the approximately 3 mL of serum obtained above using the Maxwell® RSC ccfDNA Plasma Kit (Promega). The DNA was then eluted in 50 μL of elution buffer and frozen at -20°C. Since the amount of DNA required for the enzyme treatment in Example 1 above was 10 μL, a total of five enzyme treatments could be performed with the 50 μL DNA solution. Since the 10 μL of DNA required for one enzyme treatment was derived from 0.2 mL of serum, it can be said that methylation analysis is possible with a small amount of serum. In the digital PCR reaction for the methylation analysis described below, half of the enzyme-treated DNA sample (5 μL of DNA, 0.1 mL of serum-derived DNA) was used for one test.
[0103] (Methylation Analysis) The copy numbers of methylated SEPT9 (mSEPT9) and methylated HOXA1 (mHOXA1) were measured by first performing the same enzyme treatment as in Example 1 above, and then using the enzyme-reacted DNA (including 0.1 mL of serum-derived DNA), specific regions of the SEPT9 gene and HOXA1 gene were amplified by multiplex digital PCR to measure the copy numbers. In the digital PCR procedure, the DNA-containing PCR reaction solution was the same as in Example 1 above, except that it was prepared by mixing 8 μL of the enzyme-reacted DNA solution treated under Condition 1 or Condition 2 above with 14 μL of PCR reaction solution.
[0104] (Statistical Analysis) A statistical analysis was performed on the relationship between the four measured indices (mSEPT9, mHOXA1, AFP, PIVKA-II) and the subjects' clinicopathological background. GraphPad Prism ver. 9 (GraphPad Software) and StatFlex ver. 7 (Artec) were used for the analysis. For continuous variables, the Mann-Whitney U test was used to test two groups, and the Kruskal-Wallis test and Dunn's test were used for multiple comparisons. The chi-square test and Fisher's exact test were used to test categorical variables. Multiple logistic regression analysis was used for multivariate analysis. For each test marker, a receiver operating characteristic (ROC) analysis was performed to compare the diagnostic performance of the hepatocellular carcinoma patient group with that of the control group. The area under curve (AUC) was calculated based on the ROC curve. A statistically significant difference was determined at p<0.05. Furthermore, a cutoff value was set using the Youden Index, and the sensitivity and specificity were calculated.
[0105] First, the analysis results of the control group and all viral hepatocellular carcinoma patient groups (Viral All Stage) are shown in FIG. 3, and the analysis results of the control group and non-viral hepatocellular carcinoma patient groups (non-Viral All Stage) are shown in FIG.
[0106] As shown in Figures 3 and 4, in both viral and non-viral hepatocellular carcinoma patient groups, when mSEPT9 or mHOXA1 was combined with AFP and PIVKA-II, both sensitivity and specificity were improved compared to AFP or PIVKA-II alone, or when the two indices AFP and PIVKA-II were used, and the AUC was also improved. In particular, in the non-viral hepatocellular carcinoma patient group shown in Figure 4, when the three indices were used, compared to AFP alone, the sensitivity was improved by 27% when mSEPT9 was used, and by 28% when mHOXA1 was used, assuming a specificity of 80%, and the AUC was also improved by 0.17 or more.
[0107] Next, the analysis results of the control group and the early viral hepatocellular carcinoma patient group (Early Viral) are shown in FIG. 5, and the analysis results of the control group and the early non-viral hepatocellular carcinoma patient group (Early NonViral) are shown in FIG.
[0108] As shown in Figures 5 and 6, even in early-stage hepatocellular carcinoma, when mSEPT9 or mHOXA1 was combined with AFP and PIVKA-II, both sensitivity and specificity were improved compared to AFP or PIVKA-II alone, or when the two indices AFP and PIVKA-II were used, and the AUC was also improved. In particular, in the group of patients with non-viral early-stage hepatocellular carcinoma shown in Figure 6, when specificity was set at 80% compared to AFP alone, the sensitivity was improved by 27% when mSEPT9 was used and by 29% when mHOXA1 was used, and the AUC was also improved by 0.23 or more.
[0109] Next, to further improve accuracy, each index was logarithmically transformed to a normal distribution and then analyzed. The subjects were the same as the Control group (n=247) and HCC group (n=269) in Table 3 above.
[0110] As a statistical analysis, a predicted value was calculated using the following formula (I) or (II): First, the predicted value according to formula (I) will be explained.
[0111]
[0112] In the above formula (I), β0 is the intercept (constant term), β1 to β5 are regression coefficients, Sex is gender (1 is substituted for females and 0 for males), Age is age, norm_APF is normally distributed AFP values, norm_PIVKA-II is normally distributed PIVKA-II values, and norm_mSEPT9 is normally distributed methylated SEPT9 values. "norm" means normally distributed.
[0113] β 0 ~β 5 is as follows.
[0114]
[0115] The normal distribution was processed using the BOX-COX transformation and logarithmic transformation based on the following formula (III), where p is a power coefficient and x is each value. When p>0, the following formula (III) was applied, and when p=0, a logarithmic transformation was performed.
[0116]
[0117] Next, the predicted value according to formula (II) will be explained.
[0118]
[0119] In the above formula (II), β0 is the intercept (constant term), β1 to β5 are regression coefficients, Sex is gender (1 for female, 0 for male), Age is age, norm_APF is normally distributed AFP value, norm_PIVKA-II is normally distributed PIVKA-II value, and norm_mHOXA1 is normally distributed methylated HOXA1 value. "norm" means normally distributed.
[0120] β 0 ~β 5 is as follows.
[0121]
[0122] The normal distribution was processed using the BOX-COX transformation and logarithmic transformation based on the following formula (V), where p is the power coefficient and x is each value. When p > 0, the following formula (V) was applied, and when p = 0, a logarithmic transformation was performed.
[0123]
[0124] In ROC analysis using a combination of AFP, PIVKA-II, and mSEPT9 to distinguish between a control group and a hepatocellular carcinoma patient group, the ability to discriminate between hepatocellular carcinoma when the combination is normally distributed and when it is not is shown in Figure 7. In addition, in ROC analysis using a combination of AFP, PIVKA-II, and mHOXA1 to distinguish between a control group and a hepatocellular carcinoma patient group, the ability to discriminate between hepatocellular carcinoma when the combination is normally distributed and when it is not normally distributed is shown in Figure 8.
[0125] 7 and 8, it was clear that the AUC value was high when AFP, PIVKA-II, mSEPT9, and mHOXA1, especially PIVKA-II, were normally distributed. Furthermore, even when PIVKA-II was combined with mSEPT9 or mHOXA1 without AFP, the AUC was high at 0.935 when PIVKA-II was normally distributed.
[0126] Next, when AFP, PIVKA-II, and mSEPT9, which had high AUC values, were all normally distributed, and when AFP, PIVKA-II, and mHOXA1 were all normally distributed, the patients were divided into overall HCC, early HCC, early non-viral HCC, and early viral HCC, and after adding age and sex as factors, multiple logistic regression analysis was performed. AUC was calculated for each of these parameters alone using ROC analysis. mSEPT9 hepatocellular carcinoma overall is shown in Figure 9A, early hepatocellular carcinoma, early non-viral hepatocellular carcinoma, early viral hepatocellular carcinoma is shown in Figure 9B, mHOXA1 hepatocellular carcinoma overall is shown in Figure 10A, early hepatocellular carcinoma, early non-viral hepatocellular carcinoma, early viral hepatocellular carcinoma is shown in Figure 10B. The cutoff value for mSEPT9 was calculated using the Youden Index to be 35 (copy number / mL), and the cutoff value for mHOXA1 was calculated using the Youden Index to be 310 (copy number / mL). In addition, in the predicted value of the results of multiple logistic regression analysis with all factors added, when mSEPT9 was combined using the Youden Index, 0.60 was set as the cutoff value, and when mHOXA1 was combined, 0.61 was set as the cutoff value, and the sensitivity and specificity were calculated.
[0127] As is clear from Figures 9A to 10B, it was confirmed that early stage non-viral liver cancer could be diagnosed with extremely high accuracy, and that the degree of increase in AUC was high compared to AFP or PIVKA-II alone.
[0128] Next, the correlation between mSEPT9 or mHOXA1 and AFP or PIVKA-II was examined using Spearman's correlation coefficient.
[0129] As a result, it was shown that mSEPT9 and mHOXA1 were not correlated with AFP and PIVKA-II, and could cover cases that could not be covered by AFP or PIVKA-II alone (not shown).
[0130] Next, we investigated whether methylation analysis was possible with small amounts of serum. Frozen serum samples were thawed, and DNA was extracted from 1.0 mL (1000 μL) of serum sample using the Maxwell® RSC ccfDNA plasma Kit (Promega). DNA was also extracted similarly from 0.4 mL (400 μL) of serum sample. Each was eluted in 50 μL of elution buffer. Each DNA sample was subjected to the single treatment described in Example 1, Condition 1, and then the copy number of methylated SEPT9 (mSEPT9) was measured and compared. The same procedure was performed for methylated HOXA1 (mHOXA1). The results are shown in Figure 11.
[0131] There was no difference in mSEPT9 measurements (copy number / mL serum) between DNA extracted from 1.0 mL serum samples and DNA extracted from 0.4 mL serum samples, with both showing nearly identical values. Similar results were also obtained for mHOXA1 copy number. From the above, it was found that methylation analysis is possible with a serum volume of 0.4 mL. Since the amount of DNA required for the enzyme treatment in Example 1 is 10 μL, a total of five enzyme treatments can be performed using the 50 μL of eluted DNA solution. When 0.4 mL of serum is used for DNA extraction, the 10 μL of DNA required for one enzyme treatment is derived from 0.08 mL of serum. Since half of that amount is sufficient for PCR, it can be said that methylation analysis is possible with as little as 0.04 mL of serum.
Claims
1. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject, comprising: (A) measuring the CpG methylation level in the transcriptional regulatory region and / or the region of the transcriptional start site of the SEPT9 gene in DNA extracted from a body fluid collected from a subject, or the CpG methylation level in the transcriptional regulatory region and / or the region of the transcriptional start site of the HOXA1 gene in DNA extracted from the body fluid collected from the subject; and (B) measuring the α-fetoprotein (AFP) level or protein induced by vitamin K absorption or antagonist-II (PIVKA-II) level in the body fluid collected from the subject, performing a statistical analysis based on at least the two indices (A) and (B), and based on the value obtained by the statistical analysis, The methylation level of CpG in the transcriptional regulatory region of the SEPT9 gene and / or the region of the transcription start site +1 to +1000, or the transcriptional regulatory region of the HOXA1 gene and / or the region of the transcription start site +1 to +1000, is measured by: (ii) adding at least one restriction enzyme selected from HhaI, HpaII, Hpy99I, SacII, SmaI, NotI, AatII, AccI, Aor13HI, Aor51HI, BspT104I, BssHII, Cfr10I, ClaI, CpoI, Eco52I, HaeII, MluI, NaeI, NruI, PmaCI, Psp1406I, PvuI, SalI, and SnaBI, (iii) the restriction enzyme BstUI, and (iv) a restriction enzyme reaction buffer, and sealing the reaction vessel; (b) treating the reaction vessel with the restriction enzyme at a temperature of 30 to 50° C. for 0.5 to 16 hours, and then at 50 to 70° C. for 0.5 to 20 hours while keeping the reaction vessel sealed; (c) amplifying a part or all of the transcriptional regulatory region and / or the region from +1 to +1000 of the transcriptional start site of the gene to be measured using the DNA treated with the restriction enzyme in step (b) as a template; (d) measuring the methylation level of CpG in the DNA of the transcriptional regulatory region and / or the region from +1 to +1000 of the transcriptional start site to be amplified in step (c) based on the results of the amplification in step (c);a method for measuring a methylation level of CpG in a region of a transcriptional regulatory region and / or a region of a transcriptional start site of a gene to be measured, comprising steps (a) to (d) above, characterized in that the DNA in the region of a transcriptional regulatory region and / or a region of a transcriptional start site of a gene to be measured that is the target of amplification in step (c) contains one or more sequences recognized by the restriction enzyme used in step (a); 2. The method for assisting in the diagnosis of hepatocellular carcinoma according to claim 1, characterized in that the body fluid is 0.01 to 1 mL of serum.
3. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to claim 1 or 2, characterized in that logarithmic transformation of AFP level or PIVKA-II level is used in the statistical analysis.
4. A method for assisting in the diagnosis of hepatocellular carcinoma according to claim 1 or 2, characterized in that the statistical analysis is performed based on three indicators: the CpG methylation level, AFP level, and PIVKA-II level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the SEPT9 gene; or the CpG methylation level, AFP level, and PIVKA-II level in DNA in the region +1 to +1000 of the transcriptional regulatory region and / or transcription start point of the HOXA1 gene.
5. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to claim 1 or 2, wherein the hepatocellular carcinoma is non-viral hepatocellular carcinoma.
6. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject as described in claim 1 or 2, comprising: performing a statistical analysis based on at least the above two indicators (A) and (B); comparing a value obtained by said statistical analysis with a value obtained by said statistical analysis in a control subject not suffering from hepatocellular carcinoma; and assessing that the subject is highly likely to be suffering from hepatocellular carcinoma when the value obtained by the statistical analysis based on at least the above two indicators (A) and (B) is higher than the value obtained by said statistical analysis in a control subject not suffering from hepatocellular carcinoma.
7. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to claim 1 or 2, characterized in that the cytosine of the CpG for which the methylation level is measured in the region of +1 to +1000 of the transcriptional regulatory region and / or transcription start site of the SEPT9 gene is the cytosine at position 75,369,591, 75,369,593, 75,369,600 or 75,369,602 of human chromosome 17.
8. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to claim 1 or 2, characterized in that the cytosine of the CpG for which the methylation level is measured in the region of the transcriptional regulatory region and / or transcription start site of the HOXA1 gene between +1 and +1000 is the cytosine at position 27,095,945 of human chromosome 7.
9. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject described in claim 1 or 2, characterized in that the DNA in the transcriptional regulatory region and / or the region from +1 to +1000 of the transcription start point targeted for amplification in step (c) contains a total of one to four sequences recognized by the restriction enzyme used in step (a).
10. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject described in claim 1 or 2, characterized in that when two or more types of restriction enzymes are used in step (a), the DNA in the transcriptional regulatory region and / or the region from +1 to +1000 of the transcription start point to be amplified in step (c) does not contain a sequence recognized by at least one of the restriction enzymes used in step (a).
11. A method for assisting in the diagnosis of hepatocellular carcinoma in a subject according to claim 1 or 2, characterized in that in step (a), at least HhaI, HpaII and BstUI are added as restriction enzymes to the reaction vessel.
Citation Information
Patent Citations
Methods and kits for detecting pancreatic cancer
JP2017086043A
Methods and compositions for generating and amplifying DNA libraries for sensitive detection and analysis of DNA methylation
US20130309668A1
Methods and compositions for detecting genetic material
US20220362764A1
Biomarkers for down syndrome prenatal diagnosis
WO2014051522A1
Method for testing for colon tumors
WO2017043497A1
